Bile acid profiling as an effective biomarker for staging in pediatric inflammatory bowel disease

References

• de Souza HSP, Fiocchi C, Iliopoulos D. The IBD interactome: an integrated view of aetiology, pathogenesis and therapy. Nat Rev Gastroenterol Hepatol. 2017;14(12):739–16. doi:10.1038/nrgastro.2017.110.
   PubMed Web of Science ®Google Scholar
• Lopes EW, Chan SSM, Song M, Ludvigsson JF, Håkansson N, Lochhead P, Clark A, Burke KE, Ananthakrishnan AN, Cross AJ. et al. Lifestyle factors for the prevention of inflammatory bowel disease. Gut. 2022;72(6):1093–1100. doi:10.1136/gutjnl-2022-328174.
   Web of Science ®Google Scholar
• Starr AE, Deeke SA, Ning Z, Chiang CK, Zhang X, Mottawea W. et al. Proteomic analysis of ascending colon biopsies from a paediatric inflammatory bowel disease inception cohort identifies protein biomarkers that differentiate Crohn’s disease from UC. Gut. 2017;66:1573–83. doi:10.1136/gutjnl-2015-310705.
   PubMed Web of Science ®Google Scholar
• Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021;18(1):56–66. doi:10.1038/s41575-020-00360-x.
   PubMed Web of Science ®Google Scholar
• Jang HJ, Kang B, Choe BH. The difference in extraintestinal manifestations of inflammatory bowel disease for children and adults. Transl Pediatr. 2019;8(1):4–15. doi:10.21037/tp.2019.01.06.
   PubMed Web of Science ®Google Scholar
• Oliveira SB, Monteiro IM. Diagnosis and management of inflammatory bowel disease in children. Bmj 2017; 357:j2083.
   Google Scholar
• Argollo M, Kotze PG, Kakkadasam P, D’Haens G. Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring? Nat Rev Gastroenterol Hepatol. 2020;17(11):702–10. doi:10.1038/s41575-020-0352-2.
   PubMed Web of Science ®Google Scholar
• Shen B. IBD: step-up vs top-down therapy for Crohn’s disease: medicine vs surgery. Nat Rev Gastroenterol Hepatol. 2017;14(12):693–695. doi:10.1038/nrgastro.2017.139.
   PubMed Web of Science ®Google Scholar
• Morita M, Takedatsu H, Yoshioka S, Mitsuyama K, Tsuruta K, Kuwaki K, Kato K, Yasuda R, Mizuochi T, Yamashita Y. et al. Utility of diagnostic colonoscopy in pediatric intestinal disease. J Clin Med. 2022;11(19):11. doi:10.3390/jcm11195747.
   Web of Science ®Google Scholar
• Sturm A, Maaser C, Calabrese E, Annese V, Fiorino G, Kucharzik T, Vavricka SR, Verstockt B, van Rheenen P, Tolan D. et al. ECCO-ESGAR guideline for diagnostic assessment in IBD part 2: IBD scores and general principles and technical aspects. J Crohns Colitis. 2019;13(3):273–84. doi:10.1093/ecco-jcc/jjy114.
   PubMed Web of Science ®Google Scholar
• Jukic A, Bakiri L, Wagner EF, Tilg H, Adolph TE. Calprotectin: from biomarker to biological function. Gut. 2021;70(10):1978–88. doi:10.1136/gutjnl-2021-324855.
   PubMed Web of Science ®Google Scholar
• Sands BE. Biomarkers of inflammation in inflammatory bowel disease. Gastroenterology. 2015;149(5):1275–85.e2. doi:10.1053/j.gastro.2015.07.003.
   PubMed Web of Science ®Google Scholar
• Maaser C, Sturm A, Vavricka SR, Kucharzik T, Fiorino G, Annese V, Calabrese E, Baumgart DC, Bettenworth D, Borralho Nunes P. et al. ECCO-ESGAR guideline for diagnostic assessment in IBD part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 2019;13(2):144–164. doi:10.1093/ecco-jcc/jjy113.
   PubMed Web of Science ®Google Scholar
• Argmann C, Hou R, Ungaro RC, Irizar H, Al-Taie Z, Huang R, Kosoy R, Venkat S, Song W-M, Di’Narzo AF. et al. Biopsy and blood-based molecular biomarker of inflammation in IBD. Gut. 2022;72(7):1271–1287. doi:10.1136/gutjnl-2021-326451.
   PubMed Web of Science ®Google Scholar
• Di’narzo AF, Houten SM, Kosoy R, Huang R, Vaz FM, Hou R, Wei G, Wang W, Comella PH, Dodatko T. et al. Integrative analysis of the inflammatory bowel disease serum metabolome improves our understanding of genetic etiology and points to novel putative therapeutic targets. Gastroenterology. 2022;162(3):828–43.e11. doi:10.1053/j.gastro.2021.11.015.
   PubMed Web of Science ®Google Scholar
• Franzosa EA, Sirota-Madi A, Avila-Pacheco J, Fornelos N, Haiser HJ, Reinker S, Vatanen T, Hall AB, Mallick H, McIver LJ. et al. Gut microbiome structure and metabolic activity in inflammatory bowel disease. Nat Microbiol. 2019;4(2):293–305. doi:10.1038/s41564-018-0306-4.
   PubMed Web of Science ®Google Scholar
• Wang Y, Gao X, Zhang X, Xiao F, Hu H, Li X, Zhou Z. Intestinal Cetobacterium and acetate modify glucose homeostasis via parasympathetic activation in zebrafish. Gut Microbes. 2021;13(1):1–18. doi:10.1080/19490976.2021.1900996.
   PubMed Web of Science ®Google Scholar
• Lloyd-Price J, Arze C, Ananthakrishnan AN, Schirmer M, Avila-Pacheco J, Poon TW, Andrews E, Ajami NJ, Bonham KS, Brislawn CJ. et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature. 2019;569(7758):655–62. doi:10.1038/s41586-019-1237-9.
   PubMed Web of Science ®Google Scholar
• Diab J, Hansen T, Goll R, Stenlund H, Ahnlund M, Jensen E, Moritz T, Florholmen J, Forsdahl G. Lipidomics in ulcerative colitis reveal alteration in mucosal lipid composition associated with the disease state. Inflamm Bowel Dis. 2019;25(11):1780–1787. doi:10.1093/ibd/izz098.
   PubMed Web of Science ®Google Scholar
• Filimoniuk A, Blachnio-Zabielska A, Imierska M, Lebensztejn DM, Daniluk U. Sphingolipid analysis indicate lactosylceramide as a potential biomarker of inflammatory bowel disease in children. Biomolecules. 2020;10(7):10. doi:10.3390/biom10071083.
   Web of Science ®Google Scholar
• Graffner H, Gillberg PG, Rikner L, Marschall HU. The ileal bile acid transporter inhibitor A4250 decreases serum bile acids by interrupting the enterohepatic circulation. Aliment Pharmacol Ther. 2016;43(2):303–10. doi:10.1111/apt.13457.
   PubMed Web of Science ®Google Scholar
• Ferrebee CB, Dawson PA. Metabolic effects of intestinal absorption and enterohepatic cycling of bile acids. Acta Pharm Sin B. 2015;5(2):129–34. doi:10.1016/j.apsb.2015.01.001.
   PubMed Web of Science ®Google Scholar
• Dong D, Su T, Chen W, Wang D, Xue Y, Lu Q, Jiang C, Ni Q, Mao E, Peng Y. et al. Clostridioides difficile aggravates dextran sulfate solution (DSS)-induced colitis by shaping the gut microbiota and promoting neutrophil recruitment. Gut Microbes. 2023;15(1):2192478. doi:10.1080/19490976.2023.2192478.
   PubMed Web of Science ®Google Scholar
• Glassner KL, Abraham BP, Quigley EMM. The microbiome and inflammatory bowel disease. J Allergy Clin Immunol. 2020;145(1):16–27. doi:10.1016/j.jaci.2019.11.003.
   PubMed Web of Science ®Google Scholar
• Manichanh C, Borruel N, Casellas F, Guarner F. The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol. 2012;9(10):599–608. doi:10.1038/nrgastro.2012.152.
   PubMed Web of Science ®Google Scholar
• Guo C, Wang Y, Zhang S, Zhang X, Du Z, Li M, Ding K. Crataegus pinnatifida polysaccharide alleviates colitis via modulation of gut microbiota and SCFAs metabolism. Int J Biol Macromol. 2021;181:357–368. doi:10.1016/j.ijbiomac.2021.03.137.
   PubMed Web of Science ®Google Scholar
• Mukherjee A, Lordan C, Ross RP, Cotter PD. Gut microbes from the phylogenetically diverse genus eubacterium and their various contributions to gut health. Gut Microbes. 2020;12(1):1802866. doi:10.1080/19490976.2020.1802866.
   PubMed Web of Science ®Google Scholar
• Kong L, Lloyd-Price J, Vatanen T, Seksik P, Beaugerie L, Simon T, Vlamakis H, Sokol H, Xavier RJ. Linking strain engraftment in fecal microbiota transplantation with maintenance of remission in Crohn’s disease. Gastroenterology. 2020;159(6):2193–202.e5. doi:10.1053/j.gastro.2020.08.045.
   PubMed Web of Science ®Google Scholar
• Donnenberg MS. Pathogenic strategies of enteric bacteria. Nature. 2000;406(6797):768–74. doi:10.1038/35021212.
   PubMed Web of Science ®Google Scholar
• St Geme JW 3rd, Yeo HJ. A prototype two-partner secretion pathway: the Haemophilus influenzae HMW1 and HMW2 adhesin systems. Trends Microbiol. 2009;17(8):355–60. doi:10.1016/j.tim.2009.06.002.
   PubMed Web of Science ®Google Scholar
• Baumgart M, Dogan B, Rishniw M, Weitzman G, Bosworth B, Yantiss R, Orsi RH, Wiedmann M, McDonough P, Kim SG. et al. Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of clostridiales in Crohn’s disease involving the ileum. ISME J. 2007;1(5):403–18. doi:10.1038/ismej.2007.52.
   PubMed Web of Science ®Google Scholar
• Ni J, Wu GD, Albenberg L, Tomov VT. Gut microbiota and IBD: causation or correlation? Nat Rev Gastroenterol Hepatol. 2017;14(10):573–84. doi:10.1038/nrgastro.2017.88.
   PubMed Web of Science ®Google Scholar
• Fassarella M, Blaak EE, Penders J, Nauta A, Smidt H, Zoetendal EG. Gut microbiome stability and resilience: elucidating the response to perturbations in order to modulate gut health. Gut. 2021;70(3):595–605. doi:10.1136/gutjnl-2020-321747.
   PubMed Web of Science ®Google Scholar
• Krautkramer KA, Fan J, Bäckhed F. Gut microbial metabolites as multi-kingdom intermediates. Nat Rev Microbiol. 2021;19(2):77–94. doi:10.1038/s41579-020-0438-4.
   PubMed Web of Science ®Google Scholar
• Wahlström A, Sayin SI, Marschall HU, Bäckhed F. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 2016;24(1):41–50. doi:10.1016/j.cmet.2016.05.005.
   PubMed Web of Science ®Google Scholar
• Gadaleta RM, van Erpecum KJ, Oldenburg B, Willemsen EC, Renooij W, Murzilli S, Klomp LWJ, Siersema PD, Schipper MEI, Danese S. et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut. 2011;60(4):463–72. doi:10.1136/gut.2010.212159.
   PubMed Web of Science ®Google Scholar
• Sorrentino G, Perino A, Yildiz E, El Alam G, Bou Sleiman M, Gioiello A, Pellicciari R, Schoonjans K. Bile acids signal via TGR5 to activate intestinal stem cells and epithelial regeneration. Gastroenterology. 2020;159(3):956–68.e8. doi:10.1053/j.gastro.2020.05.067.
   PubMed Web of Science ®Google Scholar
• Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull MV, Lustig KD, Mangelsdorf DJ, Shan B. et al. Identification of a nuclear receptor for bile acids. Science. 1999;284(5418):1362–5. doi:10.1126/science.284.5418.1362.
   PubMed Web of Science ®Google Scholar
• Kawamata Y, Fujii R, Hosoya M, Harada M, Yoshida H, Miwa M, Fukusumi S, Habata Y, Itoh T, Shintani Y. et al. A G protein-coupled receptor responsive to bile acids. J Biol Chem. 2003;278(11):9435–40. doi:10.1074/jbc.M209706200.
   PubMed Web of Science ®Google Scholar
• Paik D, Yao L, Zhang Y, Bae S, D’Agostino GD, Zhang M, Kim E, Franzosa EA, Avila-Pacheco J, Bisanz JE. et al. Human gut bacteria produce ΤΗ17-modulating bile acid metabolites. Nature. 2022;603(7903):907–912. doi:10.1038/s41586-022-04480-z.
   PubMed Web of Science ®Google Scholar
• Vich Vila A, Hu S, Andreu-Sánchez S, Collij V, Jansen BH, Augustijn HE, Bolte LA, Ruigrok RAAA, Abu-Ali G, Giallourakis C. et al. Faecal metabolome and its determinants in inflammatory bowel disease. Gut. 2023;72(8):1472–85. doi:10.1136/gutjnl-2022-328048.
   PubMed Web of Science ®Google Scholar
• Manzotti C, Casazza G, Stimac T, Nikolova D, Gluud C. Total serum bile acids or serum bile acid profile, or both, for the diagnosis of intrahepatic cholestasis of pregnancy. Cochrane Database Syst Rev. 2019;7:Cd012546. doi:10.1002/14651858.CD012546.pub2.
   PubMedGoogle Scholar
• Kühn T, Stepien M, López-Nogueroles M, Damms-Machado A, Sookthai D, Johnson T, Roca M, Hüsing A, Maldonado SG, Cross AJ. et al. Prediagnostic plasma bile acid levels and colon cancer risk: a prospective study. J Natl Cancer Inst. 2020;112(5):516–24. doi:10.1093/jnci/djz166.
   PubMedGoogle Scholar
• Nho K, Kueider-Paisley A, MahmoudianDehkordi S, Arnold M, Risacher SL, Louie G, Blach C, Baillie R, Han X, Kastenmüller G. et al. Altered bile acid profile in mild cognitive impairment and Alzheimer’s disease: Relationship to neuroimaging and CSF biomarkers. Alzheimers Dement. 2019;15(2):232–44. doi:10.1016/j.jalz.2018.08.012.
   PubMed Web of Science ®Google Scholar
• Lee JWJ, Plichta D, Hogstrom L, Borren NZ, Lau H, Gregory SM, Tan W, Khalili H, Clish C, Vlamakis H. et al. Multi-omics reveal microbial determinants impacting responses to biologic therapies in inflammatory bowel disease. Cell Host Microbe. 2021;29(8):1294–304.e4. doi:10.1016/j.chom.2021.06.019.
   PubMed Web of Science ®Google Scholar
• Li J, Chen Y, Li R, Zhang X, Chen T, Mei F, Liu R, Chen M, Ge Y, Hu H. et al. Gut microbial metabolite hyodeoxycholic acid targets the TLR4/MD2 complex to attenuate inflammation and protect against sepsis. Mol Ther. 2023;31(4):1017–32. doi:10.1016/j.ymthe.2023.01.018.
   PubMed Web of Science ®Google Scholar
• Zheng X, Chen T, Jiang R, Zhao A, Wu Q, Kuang J, Sun D, Ren Z, Li M, Zhao M. et al. Hyocholic acid species improve glucose homeostasis through a distinct TGR5 and FXR signaling mechanism. Cell Metab. 2021;33(4):791–803.e7. doi:10.1016/j.cmet.2020.11.017.
   PubMed Web of Science ®Google Scholar
• Levine A, Griffiths A, Markowitz J, Wilson DC, Turner D, Russell RK, Fell J, Ruemmele FM, Walters T, Sherlock M. et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis. 2011;17(6):1314–21. doi:10.1002/ibd.21493.
   PubMed Web of Science ®Google Scholar
• Taghipour N, Molaei M, Mosaffa N, Rostami-Nejad M, Asadzadeh Aghdaei H, Anissian A, Azimzadeh P, Zali MR. An experimental model of colitis induced by dextran sulfate sodium from acute progresses to chronicity in C57BL/6: correlation between conditions of mice and the environment. Gastroenterol Hepatol Bed Bench. 2016;9:45–52.
   PubMedGoogle Scholar